BIOCRYST PHARMACEUTICALS INC (BCRX)

US09058V1035 - Common Stock

7.35  -1.08 (-12.81%)

After market: 7.3 -0.05 (-0.68%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (11/4/2024, 9:59:47 PM)

After market: 7.3 -0.05 (-0.68%)

7.35

-1.08 (-12.81%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month38.16%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.52B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BCRX Daily chart

Company Profile

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 536 full-time employees. The firm leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Company Info

BIOCRYST PHARMACEUTICALS INC

4505 Emperor Blvd Ste 200

Durham NORTH CAROLINA 27703

P: 19198591302

CEO: Jon P. Stonehouse

Employees: 536

Website: https://www.biocryst.com/

BCRX News

News Image14 hours ago - The Motley FoolBioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript

BCRX earnings call for the period ending September 30, 2024.

ChartMill News Image18 hours ago - ChartmillThese stocks are gapping in today's session

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

News Image21 hours ago - BioCryst Pharmaceuticals, Inc.BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

— Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end...

News Image15 days ago - BioCryst Pharmaceuticals, Inc.BioCryst to Report Third Quarter 2024 Financial Results on November 4

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...

News Image22 days ago - BioCryst Pharmaceuticals, Inc.BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on...

News Image25 days ago - Market News VideoRSI Alert: BioCryst Pharmaceuticals (BCRX) Now Oversold

BCRX Twits

Here you can normally see the latest stock twits on BCRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example